Previous 10 | Next 10 |
PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 15, 2022 at 11:20 a.m. P.T. ...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica ( VRCA ): Approval of its viral skin disease treatment could transform the company into a commerci...
PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Applicat...
In a down market, you can pick up the same fundamentally robust companies at a fraction of their intrinsic value. As an orphan disease innovator, BioMarin is enjoying significant and substantial revenue increases from its approved assets. Nevertheless, the company is aggressively ...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Amicus Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Amicus Therapeutics, Inc. (FOLD) Q1 2022 Earnings Conference Call May 09, 2022, 08:30 AM ET Company Participants Andrew Faughnan - Executive Director-Investor Relations John Crowley - Chairman and Chief Executive Officer Bradley Campbell - President and Chief Operating Officer Daphne Quimi - ...
1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold ® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparatio...
Amicus Therapeutics press release (NASDAQ:FOLD): Q1 GAAP EPS of -$0.30 misses by $0.04. Revenue of $78.7M (+18.5% Y/Y) beats by $1.56M. Cash, cash equivalents, and marketable securities totaled $411.2 million at March 31, 2022, compared to $482.5 million at December 31, 2021. Based on current...
1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold ® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparatio...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2024. Par...
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...